Transgender (TG) people are a NIH-designated health disparities population with high morbidity and mortality across multiple health conditions, including HIV infection, mental health, and substance use. These conditions are a product of and exacerbated by historical and ongoing discrimination and inequities in access to healthcare. In early 2020, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) was recognized as a global pandemic. To date, no data exists on COVID-19 disease in TG people. There is an urgent need to understand the burden of COVID-19 disease, investigate its impact on other health conditions and vulnerabilities burdening TG populations, and identify future public health intervention targets. The current proposal aims to fill this gap. To accomplish these goals, disparities in access to testing among TG people must be identified and mitigated. The parent LITE study enrolled a baseline sample of more than 1500 TG women in the eastern and southern U.S. to assess HIV risk across 24 months of biobehavioral follow-up using technology- enhanced, digital methods of data capture. Leveraging the LITE infrastructure and in partnership with two community-based organizations, we aim to develop LITE-CONNECT, a rapid, community-engaged mixed-methods assessment that will enroll over 2,000 TG men and women across eastern and southern U.S. The objective of this supplemental study is to characterize access and barriers to COVID-19 testing, provide access to and evaluate the use of home-based COVID-19 antibody testing to identify past infection and potential immunity, connect TG men and women to available community-based COVID-19 testing and support services, and identify community-based solutions to support access to COVID-19 testing, interventions, and care among TG people. Results from this study will be rapidly used to inform community-based efforts and national COVID-19 response that is inclusive of TG people. The proposed research will provide critical and timely insights about COVID-19 disease in TG people in a space in which almost no information currently exists. Early identification of disparities in COVID-19 morbidity and in access to COVID-19 testing and care is critical to ensuring access to services as the pandemic continues. We will leverage our existing infrastructure and community collaborations to gather new data, including unprecedented data from TG men, to guide urgently needed interventions to improve and optimize the health and wellbeing of TG people in the context of the COVID-19 pandemic.
Transgender (TG) people are a NIH-designated health disparities population with high morbidity and mortality across multiple health conditions, which are a product of and exacerbated by historical and ongoing discrimination in healthcare. To date, no data exists on COVID-19 disease in TG people, though there is an urgent need to understand the burden of COVID-19 disease, investigate its impact on other health conditions and vulnerabilities burdening TG populations, and identify future public health intervention targets. Leveraging the LITE study and ongoing partnerships with community organizations, the objective of this proposal is to address these gaps by characterizing COVID-19 testing and SARS-CoV-2 seroprevalence among 2,000 TG people in the eastern and southern U.S.
